Westport News – Six of the state’s 10 largest cities, and hundreds of others across the country, have sued OxyContin maker Purdue Pharma. So has Connecticut’s attorney general and more than 30 of his counterparts.
Robert Bird
Opioids: Boston trial opens what could be year of reckoning for executives
Purdue Pharma to research non-opioid treatments
Daily Heralds – Purdue Pharma, the controversial maker of OxyContin, and eyecare-pharmaceutical firm Ocular Therapeutix has announced a research partnership aiming to develop non-opioid pain treatments.
Read article
Point72 gender-discrimination lawsuit moves to arbitration
Purdue Pharma grapples with growing protests
Congressional Committee Investigates Purdue Pharma
Beleaguered Purdue Pharma Makes Leadership Changes
Purdue Pharma Faces Private-Sector Litigation
With Less Than 80 Days to Regulatory Deadline, Neo4j Urges Organizations to Turn GDPR Compliance Into Strategic Advantage
PR Newswire– In lead-up to GDPR’s looming May 25, 2018 deadline, Neo4j, the market leader in connected data, is urging any company that is investing in GDPR compliance to use those investments for a long-term, strategic advantage. As part of that effort, Neo4j is offering an interactive, personalized demonstration and solution assessment, which shows organizations how to use connected data to meet GDPR compliance, and also how to turn those compliance investments into a strategic advantage.